Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.02.2023 | Case report

Caplacizumab

Haemoptysis and gastrointestinal bleeding: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Agosti P, et al. Caplacizumab for the management of acute immune-mediated thrombotic thrombocytopenic purpura: Real world data from the Milan TTP Registry. Research and Practice in Thrombosis and Haemostasis 6 (Suppl. 1): abstr. PB0290, Oct 2022. Available from: URL: http://doi.org/10.1002/rth2.12788 [abstract] Agosti P, et al. Caplacizumab for the management of acute immune-mediated thrombotic thrombocytopenic purpura: Real world data from the Milan TTP Registry. Research and Practice in Thrombosis and Haemostasis 6 (Suppl. 1): abstr. PB0290, Oct 2022. Available from: URL: http://​doi.​org/​10.​1002/​rth2.​12788 [abstract]
Metadaten
Titel
Caplacizumab
Haemoptysis and gastrointestinal bleeding: 2 case reports
Publikationsdatum
01.02.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-33695-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Iobenguane

Case report

Eltrombopag